Sponsor:
Vironexis Biotherapeutics Inc.
Code:
NCT07192432
Conditions
HER2 Expressing Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dose Level 1, VNX-202
Dose Level 2, VNX-202
Dose Level 3, VNX-202
Dose Level 4, VNX-202
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-27. This information was provided to ClinicalTrials.gov by Vironexis Biotherapeutics Inc. on 2025-10-10.